Spark Therapeutics Inc to Post Q2 2018 Earnings of ($1.47) Per Share, Leerink Swann Forecasts (ONCE)
Spark Therapeutics Inc (NASDAQ:ONCE) – Investment analysts at Leerink Swann issued their Q2 2018 earnings per share (EPS) estimates for shares of Spark Therapeutics in a research note issued on Monday. Leerink Swann analyst J. Schwartz anticipates that the biotechnology company will post earnings of ($1.47) per share for the quarter. Leerink Swann currently has a “Market Perform” rating and a $49.00 target price on the stock. Leerink Swann also issued estimates for Spark Therapeutics’ Q3 2018 earnings at ($1.21) EPS.
Spark Therapeutics (NASDAQ:ONCE) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). The business had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business’s revenue was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.07) EPS.
Shares of Spark Therapeutics (NASDAQ ONCE) traded down $2.96 on Wednesday, reaching $44.76. 4,202,500 shares of the company’s stock were exchanged, compared to its average volume of 475,176. Spark Therapeutics has a one year low of $41.06 and a one year high of $91.75.
Hedge funds have recently made changes to their positions in the company. Belpointe Asset Management LLC acquired a new stake in Spark Therapeutics in the third quarter valued at $403,000. Neuberger Berman Group LLC acquired a new stake in Spark Therapeutics in the third quarter valued at $672,000. Cubist Systematic Strategies LLC raised its holdings in Spark Therapeutics by 257.7% in the third quarter. Cubist Systematic Strategies LLC now owns 8,588 shares of the biotechnology company’s stock valued at $766,000 after acquiring an additional 6,187 shares in the last quarter. Perceptive Advisors LLC acquired a new stake in Spark Therapeutics in the third quarter valued at $16,049,000. Finally, Orbimed Advisors LLC acquired a new stake in Spark Therapeutics in the third quarter valued at $38,340,000. Institutional investors and hedge funds own 94.94% of the company’s stock.
In other Spark Therapeutics news, insider Daniel Faga sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total transaction of $127,500.00. Following the completion of the sale, the insider now directly owns 1,500 shares in the company, valued at $127,500. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Stephen W. Webster sold 10,000 shares of the company’s stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $70.14, for a total transaction of $701,400.00. Following the completion of the transaction, the chief financial officer now owns 12,500 shares of the company’s stock, valued at $876,750. The disclosure for this sale can be found here. Insiders have sold 1,068,809 shares of company stock valued at $89,809,385 in the last ninety days. 7.30% of the stock is currently owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Spark Therapeutics Inc to Post Q2 2018 Earnings of ($1.47) Per Share, Leerink Swann Forecasts (ONCE)” was first published by American Banking News and is the property of of American Banking News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2017/12/13/spark-therapeutics-inc-to-post-q2-2018-earnings-of-1-47-per-share-leerink-swann-forecasts-once.html.
About Spark Therapeutics
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.